Page last updated: 2024-12-05

1-(3-trifluoromethylphenyl)piperazine

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

1-(3-trifluoromethylphenyl)piperazine: acts as serotonin agonist; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

1-(3-(trifluoromethyl)phenyl)piperazine : A N-arylpiperazine that is piperazine substituted by a 3-(trifluoromethyl)phenyl group at position 1. A serotonergic agonist used as a recreational drug. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID4296
CHEMBL ID274866
CHEBI ID83536
SCHEMBL ID231692
MeSH IDM0069893

Synonyms (102)

Synonym
BRD-K94887716-003-02-9
UPCMLD0ENAT5654924:001
BRD-K94887716-001-01-5
gtpl115
3-trifluoromethylphenylpiperazine
nsc-128882
15532-75-9
nsc128882
KBIO1_000823
DIVK1C_000823
AE-641/01084056
SPECTRUM_000227 ,
1-[3-(trifluoromethyl)phenyl]piperazine
piperazine, 1-[3-(trifluoromethyl)phenyl]-
BSPBIO_002579
IDI1_000823
BPBIO1_000221
SPECTRUM5_001131
BIOMOL-NT_000117
tfmpp
NCGC00163171-01
nsc 128882
1-(3-(trifluoromethyl)phenyl)piperazine
1-(3-trifluoromethylphenyl)piperazine
einecs 239-574-4
n-(alpha,alpha,alpha-trifluoro-3-tolyl)piperazine
KBIO3_001799
KBIO2_005843
KBIO2_003275
KBIOGR_001480
KBIO2_000707
KBIOSS_000707
NINDS_000823
SPECTRUM4_001090
SPECTRUM2_001573
SPECTRUM3_000970
SPBIO_001506
NCGC00163171-02
1-(3-trifluoromethyl)phenylpiperazine
T-6427
STK397247
L001047
chebi:83536 ,
CHEMBL274866 ,
kkimdkmetppurn-uhfffaoysa-
inchi=1/c11h13f3n2/c12-11(13,14)9-2-1-3-10(8-9)16-6-4-15-5-7-16/h1-3,8,15h,4-7h2
bdbm50007406
1-(3-trifluoromethyl-phenyl)-piperazine
1-(3-trifluoromethyl-phenyl)-piperazine(tfmpp)
AKOS000120334
1-(m-trifluoromethylphenyl)piperazine
n-(3-trifluoromethylphenyl)piperazine
1-[3-(trifluoromethyl)phenyl]-piperazine
legal x [street name]
25r3onu51c ,
unii-25r3onu51c
legal e [street name]
trifluoromethylphenylpiperazine
AM20060396
AB00053672-06
piperazine, 1-(3-(trifluoromethyl)phenyl)-
flibanserin metabolite m30a
piperazine, 1-(.alpha.,.alpha.,.alpha.-trifluoro-m-tolyl)-
j209.034a ,
tftp
BBL020111
SCHEMBL231692
3-trifluoromethyl phenyl piperazine
4-(3-(trifluoromethyl)phenyl)piperazine
n-[3-(trifluoromethyl) phenyl]-piperazine
1-[3-(trifluoromethyl)-phenyl]-piperazine
n-(alpha, alpha, alpha-trifluoro-m-tolyl)piperazine
n-(alpha,alpha,alpha-trifluoro-m-tolyl)-piperazine
n-(alpha,alpha,alpha-trifluoro-m-tolyl)piperazine
4-(3-trifluoromethyl- phenyl)-piperazine
(3-trifluoromethylphenyl)piperazine
1-(3-trifluoromethylphenyl)-piperazine
4-(3-trifluoromethylphenyl)piperazine
n-(alpha, alpha, alphatrifluoro-m-tolyl)piperazine
1-(3-(trifluoromethyl)phenyl) piperazine
3-trifluoro methylphenylpiperazine
1-(alpha,alpha,alpha-trifluoro-m-tolyl)piperazine
1-(alpha,alpha,alpha-trifluoro-meta-tolyl)piperazine
(3-trifluoromethylphenyl) piperazine
n-(alpha, alpha, alpha-trifluoro-m-tolyl)-piperazine
4-(3-trifluoromethyl-phenyl)-piperazine
n-[3-(trifluoromethyl)phenyl]piperazine
1-(3-trifluoromethyl-phenyl)piperazine
4-(3-trifluoromethyl-phenyl)piperazine
n-(3-trifluoromethylphenyl)-piperazine
3-trifluoromethylphenyl piperazine
1-(alpha, alpha, alpha-trifluoro-m-tolyl)piperazine
J-503381
m-trifluoromethylphenylpiperazine
TS-03280
1-(m-trifluoromethylphenyl) piperazine
DTXSID10165876
CS-W007879
m-trifluorophenylpiperazine (tfmpp)
1-(alpha,alpha,alpha-trifluoro-m-tolyl)piperazine, analytical standard, 96%
Q419405
dblhgnabggdrjq-uhfffaoysa-n

Research Excerpts

Toxicity

ExcerptReferenceRelevance
" The use of these party pills has been associated with adverse health effects."( Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand.
Girling, M; Sweetsur, P; Wilkins, C, 2008
)
0.35
" Multiple logistic regression analysis was used to identify independent predictors of having experienced adverse side effects from party pills."( Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand.
Girling, M; Sweetsur, P; Wilkins, C, 2008
)
0.35
" Being female, using cannabis and other drugs concurrently with BZP/TFMPP party pills, taking large quantities of party pills in a single session and taking 5-hydroxytryptophan (5-HTP) recovery pills at the same time as party pills were independent predictors of having experienced an adverse problem from party pills."( Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand.
Girling, M; Sweetsur, P; Wilkins, C, 2008
)
0.35
" Taking 5-HTP 'recovery' pills with party pills may increase the risk of adverse effects as both substances increase users' levels of serotonin."( Patterns of benzylpiperazine/trifluoromethylphenylpiperazine party pill use and adverse effects in a population sample in New Zealand.
Girling, M; Sweetsur, P; Wilkins, C, 2008
)
0.35
"Lack of quality control in party pill manufacture may have led to the toxic effects reported by users unaware of the true content and release of drug from pills."( Pharmaceutical quality of "party pills" raises additional safety concerns in the use of illicit recreational drugs.
Antia, U; Fredatovich, JD; Na, Y; Neale, PT; Roberts, AF; Russell, B; Thrimawithana, TR; Young, SA; Zhou, H, 2013
)
0.39
" Piperazine designer drugs were synthesized as an alternative to MDMA and have shown to induce numerous toxic effects leading to huge health, safety, law enforcement & monetary problems, and lethality."( Dopaminergic neurotoxic effects of 3-TFMPP derivatives.
Almaghrabi, M; Deruiter, J; Dhanasekaran, M; Fadan, M; Fujihashi, A; Lee, W; Majrashi, M; Randall Clark, C, 2018
)
0.48

Compound-Compound Interactions

ExcerptReferenceRelevance
"The objective of this study was to determine the clinical effects of party pills containing benzylpiperazine (BZP) and trifluoromethylphenylpiperazine (TFMPP) when taken alone and in combination with alcohol."( Randomised double-blind, placebo-controlled trial of the effects of the 'party pills' BZP/TFMPP alone and in combination with alcohol.
Aldington, S; Beasley, R; Caldwell, B; Dickson, S; Lucas, N; McDowall, J; Robinson, G; Thompson, I; Weatherall, M; Williams, G, 2010
)
0.36
" The purpose of this study is to further investigate the subjective and physiological responses following an oral dose of BZP combined with TFMPP in males."( Determining the subjective and physiological effects of BZP combined with TFMPP in human males.
Jan, RK; Jensen, MA; Kydd, RR; Lee, H; Lin, JC; Russell, BR, 2011
)
0.37

Bioavailability

ExcerptReferenceRelevance
" This reduction in 5-HT neuron firing activity is a 5-HT-mediated response, due to an increased bioavailability of the neurotransmitter in the biophase of somatodendritic 5-HT1A autoreceptors."( Autoregulatory properties of dorsal raphe 5-HT neurons: possible role of electrotonic coupling and 5-HT1D receptors in the rat brain.
Blier, P; de Montigny, C; Piñeyro, G; Weiss, M, 1996
)
0.29

Dosage Studied

ExcerptRelevanceReference
" The dose injected was selected on the basis of dose-response curves."( Stimulation of 5-HT1A and 5-HT1B receptors in brain regions and its effects on male rat sexual behaviour.
Ahlenius, S; Escalante, AL; Fernández-Guasti, A; Hillegaart, V; Larsson, K, 1992
)
0.28
" A maximally effective dose of LY53857 (1 mg/kg) produced larger shifts of the dose-response curves to serotonin, 5-methoxytryptamine and alpha-methyl-serotonin than did a maximally effective dose of ketanserin (1 mg/kg)."( A pharmacologic examination of receptors mediating serotonin-induced bronchoconstriction in the anesthetized guinea pig.
Buckner, CK; Dea, D; Krell, RD; Liberati, N, 1991
)
0.28
" Further, in the presence of TFMPP, mCPP and DOI, the dose-response curve for the induction of tail-flicks by 8-OH-DPAT was both steeper and shifted to the left."( Agonist action at 5-HT1C receptors facilitates 5-HT1A receptor-mediated spontaneous tail-flicks in the rat.
Bervoets, K; Colpaert, FC; Millan, MJ, 1990
)
0.28
" Once criterion performance was attained, each group was tested with various doses of the drug used in their training, thus allowing for calculations of dose-response curves and ED50 values."( Stability of the stimulus properties of drugs over time.
Boja, JW; Schechter, MD; Signs, SA, 1989
)
0.28
" Since the chronic chlordiazepoxide pretreatment did not prevent the hypolocomotion or hypophagia induced by mCPP at high dosage (5 mg/kg) these latter effects are unlikely to be secondary to anxiety."( Anxiogenic-like effects of mCPP and TFMPP in animal models are opposed by 5-HT1C receptor antagonists.
Curzon, G; Kennett, GA; Shah, K; Whitton, P, 1989
)
0.28
" Pretreatment with 4 mumol/kg of 1-NP shifted the entire dose-response curve for head-twitching induced by quipazine (0."( Properties of some 1-arylpiperazines as antagonists of stereotyped behaviors mediated by central serotonergic receptors in rodents.
Schechter, LE; Simansky, KJ, 1988
)
0.27
" Low microiontophoretic currents of ipsapirone and LY 165163 were also effective in suppressing spontaneous firing; dose-response relationships for the 5-HT1A compounds were indistinguishable from that of 5-HT itself."( Electrophysiological responses of serotoninergic dorsal raphe neurons to 5-HT1A and 5-HT1B agonists.
Aghajanian, GK; Sprouse, JS, 1987
)
0.27
" Results indicate that the 5HT1B receptor agonists TFMPP and m-CPP substitute for THBC in a dose-response manner whereas 5HT1A agonists do not generalize to the THBC-induced discriminative stimulus."( Tetrahydro-beta-carboline may produce its stimulus effects via 5HT1B receptors.
Schechter, MD, 1987
)
0.27
" pretreatment (25 min) with morphine sulfate, 8-OH-DPAT, buspirone and 5-CT shifted the morphine sulfate dose-response curve 3- to 5-fold to the right."( Differential roles of 5-hydroxytryptamine1A and 5-hydroxytryptamine1B receptor subtypes in modulating spinal nociceptive transmission in mice.
Alhaider, AA; Wilcox, GL, 1993
)
0.29
"), a 5-HT1A receptor agonist, induced penile erection and yawning with a U-inverted dose-response curve in male rats."( Penile erection and yawning induced by 5-HT1C receptor agonists in male rats: relationship with dopaminergic and oxytocinergic transmission.
Argiolas, A; Melis, MR; Stancampiano, R, 1994
)
0.29
" The time-course excretion profiles of TFMPP and p-OH-TFMPP in rats were investigated following a single intraperitoneal dosing of 5 mg kg(-1) TFMPP by using an optimized analytical procedure that combined solid-phase extraction and LC-ESI MS techniques."( Isolation, identification and excretion profile of the principal urinary metabolite of the recently banned designer drug 1-(3-trifluoromethylphenyl)piperazine (TFMPP) in rats.
Inoue, H; Kamata, T; Katagi, M; Kishi, T; Miki, A; Nakajima, K; Shima, N; Tsuchihashi, H; Tsutsumi, H, 2005
)
0.54
" Users from both Islands commonly exceeded the dosage of BZP/TFMPP recommended by STANZ suggesting the STANZ code of conduct was largely ineffective."( Differences in harm from legal BZP/TFMPP party pills between North Island and South Island users in New Zealand: a case of effective industry self-regulation?
Sweetsur, P; Wilkins, C, 2010
)
0.36
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (4)

RoleDescription
xenobioticA xenobiotic (Greek, xenos "foreign"; bios "life") is a compound that is foreign to a living organism. Principal xenobiotics include: drugs, carcinogens and various compounds that have been introduced into the environment by artificial means.
environmental contaminantAny minor or unwanted substance introduced into the environment that can have undesired effects.
psychotropic drugA loosely defined grouping of drugs that have effects on psychological function.
serotonergic agonistAn agent that has an affinity for serotonin receptors and is able to mimic the effects of serotonin by stimulating the physiologic activity at the cell receptors. Serotonin agonists are used as antidepressants, anxiolytics, and in the treatment of migraine disorders.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (2)

ClassDescription
(trifluoromethyl)benzenesAn organofluorine compound that is (trifluoromethyl)benzene and derivatives arising from substitution of one or more of the phenyl hydrogens.
N-arylpiperazine
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (22)

Potency Measurements

ProteinTaxonomyMeasurementAverage (µ)Min (ref.)Avg (ref.)Max (ref.)Bioassay(s)
aldehyde dehydrogenase 1 family, member A1Homo sapiens (human)Potency39.81070.011212.4002100.0000AID1030
histone acetyltransferase KAT2A isoform 1Homo sapiens (human)Potency1.58490.251215.843239.8107AID504327
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
5-hydroxytryptamine receptor 3EHomo sapiens (human)Ki1.39000.00100.88359.9000AID6343
5-hydroxytryptamine receptor 3BHomo sapiens (human)Ki1.39000.00100.87119.9000AID6343
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)IC50 (µMol)0.57000.00040.629810.0000AID4802
5-hydroxytryptamine receptor 2CRattus norvegicus (Norway rat)Ki0.11700.00020.667710.0000AID5234; AID5268; AID5273
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)IC50 (µMol)0.57000.00040.908610.0000AID4802
5-hydroxytryptamine receptor 2ARattus norvegicus (Norway rat)Ki0.11700.00010.601710.0000AID5234; AID5268; AID5273
Alpha-1B adrenergic receptorRattus norvegicus (Norway rat)Ki0.33700.00010.949010.0000AID37324
DRattus norvegicus (Norway rat)Ki1.00000.00010.610010.0000AID61492
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)IC50 (µMol)0.29000.00031.38338.4000AID3771
5-hydroxytryptamine receptor 1ARattus norvegicus (Norway rat)Ki0.13440.00010.739610.0000AID3684; AID3695; AID37324; AID4007; AID4062; AID4411
Alpha-1D adrenergic receptorRattus norvegicus (Norway rat)Ki0.33700.00000.575110.0000AID37324
5-hydroxytryptamine receptor 1DHomo sapiens (human)IC50 (µMol)0.61000.00050.28702.4000AID4532
5-hydroxytryptamine receptor 2CHomo sapiens (human)IC50 (µMol)0.15000.00011.03029.0000AID4743
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)IC50 (µMol)0.03900.00051.48357.8000AID4674; AID4675
5-hydroxytryptamine receptor 1BRattus norvegicus (Norway rat)Ki0.01800.00031.29679.2440AID3684; AID3695; AID4694; AID4699
5-hydroxytryptamine receptor 1DRattus norvegicus (Norway rat)Ki0.01990.00101.67479.2000AID3684; AID3695
5-hydroxytryptamine receptor 1FRattus norvegicus (Norway rat)Ki0.01990.00101.67479.2000AID3684; AID3695
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)IC50 (µMol)0.57000.00040.615610.0000AID4802
5-hydroxytryptamine receptor 2BRattus norvegicus (Norway rat)Ki0.11700.00020.590910.0000AID5234; AID5268; AID5273
Alpha-1B adrenergic receptorHomo sapiens (human)Ki0.33700.00000.471310.0000AID37324
Alpha-1A adrenergic receptorRattus norvegicus (Norway rat)Ki0.33700.00000.965010.0000AID37324
5-hydroxytryptamine receptor 3AHomo sapiens (human)Ki1.39000.00000.74119.9000AID6343
D(2) dopamine receptorRattus norvegicus (Norway rat)Ki0.53000.00000.437510.0000AID65097
5-hydroxytryptamine receptor 3DHomo sapiens (human)Ki1.39000.00100.88359.9000AID6343
5-hydroxytryptamine receptor 3CHomo sapiens (human)Ki1.39000.00100.88359.9000AID6343
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (40)

Processvia Protein(s)Taxonomy
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3EHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3EHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3EHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3BHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3BHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3BHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3BHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
intestine smooth muscle contraction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of locomotion5-hydroxytryptamine receptor 1DHomo sapiens (human)
vasoconstriction5-hydroxytryptamine receptor 1DHomo sapiens (human)
regulation of behavior5-hydroxytryptamine receptor 1DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 1DHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 1DHomo sapiens (human)
adenylate cyclase-inhibiting serotonin receptor signaling pathway5-hydroxytryptamine receptor 1DHomo sapiens (human)
behavioral fear response5-hydroxytryptamine receptor 2CHomo sapiens (human)
intracellular calcium ion homeostasis5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
phospholipase C-activating serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
locomotory behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
feeding behavior5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of phosphatidylinositol biosynthetic process5-hydroxytryptamine receptor 2CHomo sapiens (human)
cGMP-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of nervous system process5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of appetite5-hydroxytryptamine receptor 2CHomo sapiens (human)
regulation of corticotropin-releasing hormone secretion5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of fat cell differentiation5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of calcium-mediated signaling5-hydroxytryptamine receptor 2CHomo sapiens (human)
release of sequestered calcium ion into cytosol5-hydroxytryptamine receptor 2CHomo sapiens (human)
positive regulation of ERK1 and ERK2 cascade5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathway, coupled to cyclic nucleotide second messenger5-hydroxytryptamine receptor 2CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-modulating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of vasoconstrictionAlpha-1B adrenergic receptorHomo sapiens (human)
intracellular signal transductionAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of MAPK cascadeAlpha-1B adrenergic receptorHomo sapiens (human)
regulation of cardiac muscle contractionAlpha-1B adrenergic receptorHomo sapiens (human)
neuron-glial cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
adenylate cyclase-activating adrenergic receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
cell-cell signalingAlpha-1B adrenergic receptorHomo sapiens (human)
phospholipase C-activating G protein-coupled receptor signaling pathwayAlpha-1B adrenergic receptorHomo sapiens (human)
positive regulation of cytosolic calcium ion concentrationAlpha-1B adrenergic receptorHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3AHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3AHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3DHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3DHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3DHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3DHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin receptor signaling pathway5-hydroxytryptamine receptor 3CHomo sapiens (human)
monoatomic ion transmembrane transport5-hydroxytryptamine receptor 3CHomo sapiens (human)
excitatory postsynaptic potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
inorganic cation transmembrane transport5-hydroxytryptamine receptor 3CHomo sapiens (human)
regulation of membrane potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
chemical synaptic transmission5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (13)

Processvia Protein(s)Taxonomy
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3EHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3EHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3BHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3BHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3BHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 1DHomo sapiens (human)
Gq/11-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
1-(4-iodo-2,5-dimethoxyphenyl)propan-2-amine binding5-hydroxytryptamine receptor 2CHomo sapiens (human)
neurotransmitter receptor activity5-hydroxytryptamine receptor 2CHomo sapiens (human)
protein bindingAlpha-1B adrenergic receptorHomo sapiens (human)
protein heterodimerization activityAlpha-1B adrenergic receptorHomo sapiens (human)
alpha1-adrenergic receptor activityAlpha-1B adrenergic receptorHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
identical protein binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin binding5-hydroxytryptamine receptor 3AHomo sapiens (human)
ligand-gated monoatomic ion channel activity involved in regulation of presynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3AHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3AHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3DHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3DHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3DHomo sapiens (human)
protein binding5-hydroxytryptamine receptor 3CHomo sapiens (human)
serotonin-gated monoatomic cation channel activity5-hydroxytryptamine receptor 3CHomo sapiens (human)
excitatory extracellular ligand-gated monoatomic ion channel activity5-hydroxytryptamine receptor 3CHomo sapiens (human)
transmitter-gated monoatomic ion channel activity involved in regulation of postsynaptic membrane potential5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (14)

Processvia Protein(s)Taxonomy
plasma membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3EHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3EHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3EHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3EHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3BHomo sapiens (human)
cell surface5-hydroxytryptamine receptor 3BHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3BHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3BHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3BHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 1DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 1DHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 1DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 2CHomo sapiens (human)
G protein-coupled serotonin receptor complex5-hydroxytryptamine receptor 2CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 2CHomo sapiens (human)
dendrite5-hydroxytryptamine receptor 2CHomo sapiens (human)
nucleusAlpha-1B adrenergic receptorHomo sapiens (human)
cytoplasmAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
caveolaAlpha-1B adrenergic receptorHomo sapiens (human)
nuclear membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membraneAlpha-1B adrenergic receptorHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
cleavage furrow5-hydroxytryptamine receptor 3AHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3AHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3AHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3AHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3DHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3DHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3DHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3DHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
postsynaptic membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
serotonin-activated cation-selective channel complex5-hydroxytryptamine receptor 3CHomo sapiens (human)
synapse5-hydroxytryptamine receptor 3CHomo sapiens (human)
transmembrane transporter complex5-hydroxytryptamine receptor 3CHomo sapiens (human)
neuron projection5-hydroxytryptamine receptor 3CHomo sapiens (human)
plasma membrane5-hydroxytryptamine receptor 3CHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (72)

Assay IDTitleYearJournalArticle
AID1345154Rat 5-HT6 receptor (5-Hydroxytryptamine receptors)1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Cloning and expression of a novel serotonin receptor with high affinity for tricyclic psychotropic drugs.
AID1346603Human 5-ht1e receptor (5-Hydroxytryptamine receptors)2004European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3
Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor.
AID1345170Human 5-HT6 receptor (5-Hydroxytryptamine receptors)1996Journal of neurochemistry, Jan, Volume: 66, Issue:1
Cloning, characterization, and chromosomal localization of a human 5-HT6 serotonin receptor.
AID1346603Human 5-ht1e receptor (5-Hydroxytryptamine receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID624216Agonists at Human 5-Hydroxytryptamine receptor 5-HT2C2000Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2
Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
AID1345061Mouse 5-HT5A receptor (5-Hydroxytryptamine receptors)1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Mouse 5-hydroxytryptamine5A and 5-hydroxytryptamine5B receptors define a new family of serotonin receptors: cloning, functional expression, and chromosomal localization.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)1991Molecular pharmacology, Aug, Volume: 40, Issue:2
Primary structure and functional characterization of a human 5-HT1D-type serotonin receptor.
AID624230Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e1993Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID624233Agonists at Human 5-Hydroxytryptamine receptor 5-HT1F1993Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID1346739Human 5-HT1F receptor (5-Hydroxytryptamine receptors)1993Proceedings of the National Academy of Sciences of the United States of America, Jan-15, Volume: 90, Issue:2
Cloning of another human serotonin receptor (5-HT1F): a fifth 5-HT1 receptor subtype coupled to the inhibition of adenylate cyclase.
AID624216Agonists at Human 5-Hydroxytryptamine receptor 5-HT2C2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID624235Agonists at Human 5-Hydroxytryptamine receptor 5-HT2A2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID1346867Human 5-HT2B receptor (5-Hydroxytryptamine receptors)2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID1346264Human 5-HT1B receptor (5-Hydroxytryptamine receptors)1996Journal of neurochemistry, Nov, Volume: 67, Issue:5
Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors.
AID1345235Rat 5-HT7 receptor (5-Hydroxytryptamine receptors)1993The Journal of biological chemistry, Aug-25, Volume: 268, Issue:24
Molecular cloning and expression of a 5-hydroxytryptamine7 serotonin receptor subtype.
AID624230Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e2004European journal of pharmacology, Jan-26, Volume: 484, Issue:2-3
Molecular cloning and pharmacological characterization of the guinea pig 5-HT1E receptor.
AID624230Agonists at Human 5-Hydroxytryptamine receptor 5-ht1e1996Journal of neurochemistry, Nov, Volume: 67, Issue:5
Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors.
AID624240Agonists at Rat 5-Hydroxytryptamine receptor 5-HT2B1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor.
AID1345215Mouse 5-HT7 receptor (5-Hydroxytryptamine receptors)1993Molecular pharmacology, Aug, Volume: 44, Issue:2
Molecular cloning of a mammalian serotonin receptor that activates adenylate cyclase.
AID1346264Human 5-HT1B receptor (5-Hydroxytryptamine receptors)1992Proceedings of the National Academy of Sciences of the United States of America, Apr-15, Volume: 89, Issue:8
Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta.
AID1346903Rat 5-HT2B receptor (5-Hydroxytryptamine receptors)1993Molecular pharmacology, Mar, Volume: 43, Issue:3
Pharmacological characteristics of the newly cloned rat 5-hydroxytryptamine2F receptor.
AID1346528Human 5-HT1D receptor (5-Hydroxytryptamine receptors)1992Proceedings of the National Academy of Sciences of the United States of America, Apr-15, Volume: 89, Issue:8
Human serotonin 1D receptor is encoded by a subfamily of two distinct genes: 5-HT1D alpha and 5-HT1D beta.
AID1346603Human 5-ht1e receptor (5-Hydroxytryptamine receptors)1996Journal of neurochemistry, Nov, Volume: 67, Issue:5
Two amino acid differences in the sixth transmembrane domain are partially responsible for the pharmacological differences between the 5-HT1D beta and 5-HT1E 5-hydroxytryptamine receptors.
AID1346893Human 5-HT2C receptor (5-Hydroxytryptamine receptors)2000Synapse (New York, N.Y.), Feb, Volume: 35, Issue:2
Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors.
AID624219Agonists at Human 5-Hydroxytryptamine receptor 5-HT2B2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID1259419Human 5-HT2A receptor (5-Hydroxytryptamine receptors)2004Naunyn-Schmiedeberg's archives of pharmacology, Aug, Volume: 370, Issue:2
Pharmacological characterisation of the agonist radioligand binding site of 5-HT(2A), 5-HT(2B) and 5-HT(2C) receptors.
AID5271Evaluated for the binding affinity to rat cortical membranes at 5-hydroxytryptamine 2 receptor binding site by using [3H]- KET as a radioligand; ND means no data.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID3771Displacement of [3H]8-OH-DPAT from rat cortex 5-hydroxytryptamine 1A receptor1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole.
AID168355Stimulus generalization studies in TFMPP trained animals and the number of animals responding /number to receive dose of drug was determined at dose of 0.5 mg/kg; 6/61986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
5-HT1 and 5-HT2 binding characteristics of some quipazine analogues.
AID190889Stimulus generalization in TFMPP-trained rats at dosage 0.20 mg/kg. Number of animals responding/number of animals are 4/41986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
AID5234Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 2 receptor1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
AID4694Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1B receptor1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
AID203933Intrinsic affinity towards serotonin receptor from rat frontal cortex by displacement of [3H]spiperone.1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Bioactive conformation of 1-arylpiperazines at central serotonin receptors.
AID37324Binding affinity against rat Alpha-1 adrenergic receptor.1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
AID4062Binding affinity towards rat 5-hydroxytryptamine 1A receptor using [3H]8-OH-DPAT radioligand.1996Journal of medicinal chemistry, Oct-25, Volume: 39, Issue:22
Synthesis and structure-activity relationships of a new model of arylpiperazines. 1. 2-[[4-(o-methoxyphenyl)piperazin-1-yl]methyl]-1, 3-dioxoperhydroimidazo[1,5-alpha]pyridine: a selective 5-HT1A receptor agonist.
AID5273Binding affinity to 5-hydroxytryptamine 2 receptor in rat frontal cortical membranes by [3H]- KET displacement.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID4411Binding affinity of a compound to rat brain 5-hydroxytryptamine 1A (serotonin) receptor assayed by radiolabeled [3H]-8-OH-DPAT ligand displacement1996Journal of medicinal chemistry, Jan-05, Volume: 39, Issue:1
Binding of arylpiperazines, (aryloxy)propanolamines, and tetrahydropyridylindoles to the 5-HT1A receptor: contribution of the molecular lipophilicity potential to three-dimensional quantitative structure-affinity relationship models.
AID4743Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1C receptor of pig choroid plexus using [3H]mesulergine as the radioligand1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole.
AID65097Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against Dopamine receptor D21989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
AID174439Compound was evaluated in stimulus generalization test using animals trained to discriminate TFMPP from saline, and the drug appropriate responding at dose of 0.5 mg/kg1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
5-HT1 and 5-HT2 binding characteristics of some quipazine analogues.
AID3684Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1 receptor1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
AID4095Evaluated for binding affinity towards 5-hydroxytryptamine 1A receptor in rat brain1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Arylpiperazine derivatives as high-affinity 5-HT1A serotonin ligands.
AID61492Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against Dopamine receptor D11989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
AID192715Compound was evaluated in stimulus generalization test using animals trained to discriminate TFMPP from saline, and the mean responses per min at dose of 0.5 mg/kg1986Journal of medicinal chemistry, Nov, Volume: 29, Issue:11
5-HT1 and 5-HT2 binding characteristics of some quipazine analogues.
AID4007Binding affinity in radioreceptor binding assay by using [3H]5-HT radioligand against 5-hydroxytryptamine 1A receptor1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
AID190885Stimulus generalization in TFMPP-trained rats at dosage 0.05 mg/kg. Number of animals responding/number of animals are 4/41986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
AID4096Evaluated for the binding affinity to hippocampus striatal membranes at 5-hydroxytryptamine 1A receptor binding site by using [3H]-8-OH- DPAT as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID203932Intrinsic affinity towards serotonin receptor from rat frontal cortex by displacement of [3H]5-HT1985Journal of medicinal chemistry, Jul, Volume: 28, Issue:7
Bioactive conformation of 1-arylpiperazines at central serotonin receptors.
AID178197Effective dose in blocking conditioned avoidance responding (CAR) in the rat when administered intraperitoneally1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
AID5240Binding affinity to 5-hydroxytryptamine 2 receptor of rat cortical membranes using [3H]- DOB; ND means no data.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID5268Displacement of [3H]ketanserin from 5-hydroxytryptamine 2 receptor of rat cortex1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
AID4699Binding affinity (Ki) to rat cortical membranes at 5-HT1B binding site by using [125 I] ICYP as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID4747Evaluated for the binding affinity to porcine choroid plexus at 5-hydroxytryptamine 2C receptor binding site by using [3H]-MES as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID4674Inhibitory activity against 5-hydroxytryptamine 1B receptor of rat cortex using [3H]5-HT1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole.
AID4532Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 1D receptor of bovine caudate using [3H]5-HT as the radioligand1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole.
AID190891Stimulus generalization in TFMPP-trained rats at dosage 0.35 mg/kg. Number of animals responding/number of animals are 4/41986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
AID176672Compound was evaluated for ED50 in TFMPP-trained rats at dosage 0.50 mg/kg. Number of animals responding/number of animals are 4/41986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
AID204444Binding affinity towards sigma receptor in guinea pig brain membranes using [3H]DTG as radioligand1991Journal of medicinal chemistry, Dec, Volume: 34, Issue:12
Novel 1-phenylpiperazine and 4-phenylpiperidine derivatives as high-affinity sigma ligands.
AID4802Compound was evaluated for its inhibitory activity against 5-hydroxytryptamine 2 receptor of rat anterior cortex using [3H]ketanserin as the radioligand1990Journal of medicinal chemistry, Aug, Volume: 33, Issue:8
3-(1,2,5,6-Tetrahydropyrid-4-yl)pyrrolo[3,2-b]pyrid-5-one: a potent and selective serotonin (5-HT1B) agonist and rotationally restricted phenolic analogue of 5-methoxy-3-(1,2,5,6-tetrahydropyrid-4-yl)indole.
AID3695Evaluated for binding affinity towards rat cortical membranes at 5-hydroxytryptamine 1 receptor binding site by using [3H]-5-HT as a radioligand.1987Journal of medicinal chemistry, Jan, Volume: 30, Issue:1
Central serotonin receptors as targets for drug research.
AID190894Stimulus generalization in TFMPP-trained rats at dosage 0.50 mg/kg. Number of animals responding/number of animals are 5/51986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
AID194153The percent loss of escape responding was determined for the estimated effective dose 50 values for CAR block1989Journal of medicinal chemistry, May, Volume: 32, Issue:5
Activity of aromatic substituted phenylpiperazines lacking affinity for dopamine binding sites in a preclinical test of antipsychotic efficacy.
AID190890Stimulus generalization in TFMPP-trained rats at dosage 0.30 mg/kg. Number of animals responding/number of animals are 4/41986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
AID226485Hill coefficient in rat brain 5-hydroxytryptamine 1A assay1988Journal of medicinal chemistry, Oct, Volume: 31, Issue:10
Arylpiperazine derivatives as high-affinity 5-HT1A serotonin ligands.
AID190886Stimulus generalization in TFMPP-trained rats at dosage 0.15 mg/kg. Number of animals responding/number of animals are 3/31986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
AID190887Stimulus generalization in TFMPP-trained rats at dosage 0.1 mg/kg. Number of animals responding/number of animals are 4/41986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
AID6343Compound was tested for the inhibition of [3H]GR-65630 binding to 5-hydroxytryptamine 3 receptor expressed in NG 108-15 cells1996Journal of medicinal chemistry, Sep-27, Volume: 39, Issue:20
Structure-activity relationships for the binding of arylpiperazines and arylbiguanides at 5-HT3 serotonin receptors.
AID3694Displacement of [3H]spiperone from 5-hydroxytryptamine 1 receptor of rat cortex1986Journal of medicinal chemistry, May, Volume: 29, Issue:5
Synthesis and evaluation of phenyl- and benzoylpiperazines as potential serotonergic agents.
AID4675Concentration necessary to achieve half maximal inhibition of [125I]- Iodocyanopindolol binding to 5-hydroxytryptamine 1B receptor at 1 uM1989Journal of medicinal chemistry, Mar, Volume: 32, Issue:3
2H-[1]benzopyrano[3,4-b]pyridines: synthesis and activity at central monoamine receptors.
AID493017Wombat Data for BeliefDocking2001Journal of medicinal chemistry, Nov-08, Volume: 44, Issue:23
Structure-affinity relationships of a unique nicotinic ligand: N(1)-dimethyl-N(4)-phenylpiperazinium iodide (DMPP).
AID1159607Screen for inhibitors of RMI FANCM (MM2) intereaction2016Journal of biomolecular screening, Jul, Volume: 21, Issue:6
A High-Throughput Screening Strategy to Identify Protein-Protein Interaction Inhibitors That Block the Fanconi Anemia DNA Repair Pathway.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (271)

TimeframeStudies, This Drug (%)All Drugs %
pre-199068 (25.09)18.7374
1990's133 (49.08)18.2507
2000's40 (14.76)29.6817
2010's30 (11.07)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 16.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index16.43 (24.57)
Research Supply Index5.67 (2.92)
Research Growth Index4.46 (4.65)
Search Engine Demand Index15.26 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (16.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials7 (2.49%)5.53%
Reviews12 (4.27%)6.00%
Case Studies2 (0.71%)4.05%
Observational0 (0.00%)0.25%
Other260 (92.53%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]